Proud to have presented results of our GUIDE IBD study today in THE clinical science late-breaker session of DDW with vivid discussions.
For the first time in the IBD field, we used molecular biomarkers throughout a clinical study to guide individual therapy decisions.
For the first time in the IBD field, we used molecular biomarkers throughout a clinical study to guide individual therapy decisions.
What if your doctor could tailor treatment using your body’s molecular “fingerprint”? 🧬 The GUIDE-IBD study did just that. Twice as many patients were free of symptoms and inflammation after a year. @florian_watney @GastroFlo #DDW2025 #IBDView quoted post on X